- Motif Bio said it had signed an agreement with Lamellar Biomedical under which the companies would investigate a combination of their offerings.

The arrangement would see Motif Bio conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented technology.

Iclaprim had been granted US orphan drug designation for staphylococcus aureus pneumonia in patients with cystic fibrosis.

Lamellar's candidate LMS-611, which has mucus clearing properties, had demonstrated the enhancement of certain properties of antibiotics and had European orphan drug designation for CF.

'The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF,' Motif Bio said.

At 8:31am: [LON:MTFB] Motif Bio Plc Ord 1p share price was +1.52p at 10.2p

Story provided by